🚀 Biotech & Life Sciences Weekly Highlights 🌱

1. Privacy Under Fire: 27 states and D.C. are suing 23andMe to stop the sale of personal genetic data without consent — as Regeneron eyes acquisition during bankruptcy proceedings.
2. Organoid Innovation: Pluristyx launches the PluriForm™ Organoid Kit, dramatically cutting down organoid development timelines with ready-to-differentiate iPSCs.
3. Funding Milestone: Genesys Capital closes its largest fund yet — Genesys Ventures IV LP — backing Canadian life sciences with strong investor confidence.
4. Rare Disease Breakthroughs: Chiesi Group partners with Key2Brain AB to advance blood-brain barrier-crossing therapies for lysosomal storage disorders.
5. Next-Gen Neurotherapeutics: Enveric Biosciences secures a patent for low-hallucinogenic neuroplastogens, opening new doors in psychiatric treatment.

🔍 Stay tuned — innovation is not slowing down!

Sources

• Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent
• Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines
• Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
• Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB
• Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens
• Five BIO 2025 events you don’t want to miss
• Layoff Tracker: Gilead Cuts 36 Employees in California